drugset / Trial / NCT07591519

Clinical Trials of IBI3035 in Healthy Subjects

NCT07591519

Phase 1 Recruiting 144 enrolled Innovent Biologics (Suzhou) Co. Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

This study is a Phase I clinical trial that uses positive glucose clamping technology to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence of IBI3035 with insulin injection (Awiqli?) after a single administration in healthy male subjects

Timeline

Start
2026-05-08
Primary completion
2027-07-30
Completion
2027-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject IBI3035 Unknown 1 iu/kg Subcutaneous
Subject Insulin icodec Protein / enzyme biologic 1 iu/kg Subcutaneous

Indications

No indication recorded.